Use of Erythropoietin and Derivatives for Treatment of Hypertension
Erythropoietin (EPO), a natural hormone produced by kidneys, is associated with stimulation of red blood cell production. Recombinant human erythropoietin (rhEPO) is currently used for treatment of anemia and has powerful cardioprotective properties. Hypertension remains a major health problem and a serious risk factor for stroke and chronic heart failure. Researchers at the NIH have discovered that administering a therapeutically effective dose of rhEPO or an EPO derivative, including carbamylated erythropoietin (CEPO) and Helix B surface peptide (HBSP), acutely reduces both systolic and diastolic blood pressure via Nitric Oxide (NO) signaling. Long-term administration of HBSP prevents elevation of arterial blood pressure in an animal model of hypertension. Unlike long-term treatment with rhEPO, administration of EPO derivatives, such as HBSP, does not stimulate excessive red cell production and will be useful in the development of anti-hypertensive drugs.
|Potential Commercial Applications:||Competitive Advantages:||
Mark Talan (NIA)
Ismayil Ahmet (NIA)
Edward Lakatta (NIA)
US Application No. 61/636,547
US Application No. 61/638,328
US Application No. 61/656,698
PCT Application No. PCT/US2013/037155
The National Institute on Aging is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize a new anti-hypertensive drug based of non-erythropoietic derivatives of erythropoietin that combines vasodilative and tissue protective properties. For collaboration opportunities, please contact Vio Conley, M.S. at email@example.com. Click here to view the NIA collaborative opportunity announcement.
Vince Contreras , Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325
Rockville , MD 20852
OTT Reference No: E-158-2012/0